A relatively simple, quantitative approach is proposed to address a specific, important gap in the approach recommended by the USEPA Guidelines for Cancer Risk Assessment to address uncertainty in carcinogenic mode of action of certain chemicals when risk is extrapolated from bioassay data. These Guidelines recognize that some chemical carcinogens may have a site-specific mode of action (MOA) that is dual, involving mutation in addition to cell-killing induced hyperplasia. Although genotoxicity may contribute to increased risk at all doses, the Guidelines imply that for dual MOA (DMOA) carcinogens, judgment be used to compare and assess results obtained using separate "linear" (genotoxic) vs. "nonlinear" (nongenotoxic) approaches to low-level risk extrapolation. However, the Guidelines allow the latter approach to be used only when evidence is sufficient to parameterize a biologically based model that reliably extrapolates risk to low levels of concern. The Guidelines thus effectively prevent MOA uncertainty from being characterized and addressed when data are insufficient to parameterize such a model, but otherwise clearly support a DMOA. A bounding factor approach-similar to that used in reference dose procedures for classic toxicity endpoints-can address MOA uncertainty in a way that avoids explicit modeling of low-dose risk as a function of administered or internal dose. Even when a "nonlinear" toxicokinetic model cannot be fully validated, implications of DMOA uncertainty on low-dose risk may be bounded with reasonable confidence when target tumor types happen to be extremely rare. This concept was illustrated for a likely DMOA rodent carcinogen naphthalene, specifically to the issue of risk extrapolation from bioassay data on naphthalene-induced nasal tumors in rats. Bioassay data, supplemental toxicokinetic data, and related physiologically based pharmacokinetic and 2-stage stochastic carcinogenesis modeling results all clearly indicate that naphthalene is a DMOA carcinogen.
Introduction
This white paper aims to (1) point out how the Guidelines for Cancer Risk Assessment (USEPA, 2005) currently impedes quantitative characterization of uncertainty in carcinogenic mode of action (MOA) for chemical carcinogens that act by more than one mechanism, (2) propose a method to characterize and address MOA uncertainty in this situation, and (3) illustrate the application of the proposed method to the case of naphthalene. Specifically, a relatively simple, quantitative approach is proposed to address a specific, important gap in the approach recommended by the USEPA Guidelines for Cancer Risk Assessment to address uncertainty in carcinogenic mode of action of certain chemicals when risk is extrapolated from bioassay data. The scope of this paper does not extend to the broader question of how to integrate this specific source of model uncertainty into a comprehensive characterization of all sources of uncertainty in estimated cancer potency or risk. Such a comprehensive uncertainty characterization is not required in order to apply the proposed method, which may be implemented by straightforward extension of standard uncertainty-factor procedures already in use.
Current multistage cancer theory and the Guidelines for Cancer Risk Assessment (USEPA, 2005) recognize that a chemical carcinogen may have a site-specific mode of action (MOA) that is dual, involving mutation in addition to cell-killing induced hyperplasia, and that in such a case the relative contributions of each mode to increased risk may change as a function of dose. In contrast, the Guidelines suggest that "linear" vs. "nonlinear" approaches to risk extrapolation are dichotomous, and they vaguely recommend that in ambiguous cases, judgment should be used to compare and assess results obtained using "both" of these two approaches (see Appendix). Notably, the Guidelines are unclear about exactly how MOA uncertainty should be characterized and addressed when available bioassay and supplemental mechanistic toxicokinetic data for a given tumor site happen to meet the following conditions:
• the data clearly support a dual MOA (DMOA),
• the data establish with reasonable certainty that the default "linear" extrapolation procedure is not scientifically plausible (without at least some modification to reflect the nongenotoxic MOA exhibited by the data), but nevertheless
• the data are insufficient to parameterize a biologically based model that reliably extrapolates human (or bioassay animal) risk to very low, environmentally relevant levels of exposure.
The Guidelines do not clearly specify how to treat such a case, because they characterize such a DMOA case as "ambiguous" and recommend it be addressed only by either (or both) of two quite different dose-response extrapolation procedures: linear extrapolation for "genotoxic"
carcinogens, and traditional nonlinear uncertainty-factor methodology for "nongenotoxic"
carcinogens. Specifically, the Guidelines recommend that "If there are multiple modes of action at a single tumor site, one linear and another nonlinear, then both approaches are used to decouple and consider the respective contributions of each mode of action in different dose ranges" (see Appendix). The "catch-22" is that, for nongenotoxic carcinogens, the Guidelines elsewhere allow this recommendation to be pursued only when available data either (a) clearly demonstrate that an exclusively nongenotoxic MOA is applicable, or (b) establish and validate a comprehensive toxicokinetic model applicable to the carcinogen in question. Option (a) is by definition inapplicable to any DMOA carcinogen, and a comprehensive toxicokinetic model to pursue option (b) has not yet been accepted for regulatory application to any carcinogen (with a DMOA, or any other MOA). To pursue option (b), the Guidelines appear to require that a biologically based a toxicokinetic model be validated for application at all dose levels, before any consideration may be given to any of its logical implications that are based on convincing mechanistic data.
For example, suppose histological evidence from a positive chemical carcinogen bioassay indicated unambiguously that dose-related cell-killing had induced regenerative hyperplasia at multiple sites of tumorigenesis in cells histologically related to, and plausibly precursors of, dose-related tumors of types i each observed to occur at a rate R i significantly elevated above its corresponding background tumor rate (r i ). Further assume that no tumor types were significantly elevated other than those also associated in each case with histologically related hyperplasia, that the chemical is known from in vitro and in vivo studies to be cytotoxic particularly to cells of types that occur at only sites of observed dose-related tumorigenesis, and that species-and sitespecific cytotoxicity of the compound is predicted by detailed and validated physiologically based pharmacokinetic (PBPK) modeling. Based on current mechanistic-multistage cancer theory (e.g., Moolgavkar, 1983; Bogen, 1989) , the observed dose-induced, histologically linked regenerative hyperplasia would almost certainly have contributed to amplification of R i , albeit by unknown relative site-specific factors F h , where F h ≤ R i /r i . Absent evidence of genotoxicity by the test chemical or any of its metabolites, it could be argued that this chemical has a nongenotoxic MOA with F h = R i /r i . Now we add a final assumption that the chemical involved and/or its metabolite(s) is known to be genotoxic. Even with this final assumption, it still would be scientifically implausible to claim F h = 1, given the assumed histological and mechanistic evidence. While the evidence that F h > 1 is convincing in this hypothetical case, the magnitude by which F h is >1 remains uncertain. A biologically based 2-stage "MVK" or "cell kinetic" type of cancer model could in this case realistically reflect the high likelihood that both genotoxic and hyperplastic (nongenotoxic) MOAs act jointly, via a DMOA, to produce the observed response (Moolgavkar, 1983; Bogen, 1989) .
Within this MVK-type modeling framework, dose-induced regenerative cell renewal may act to boost the net rate of proliferation (birth minus death/differentiation) of surviving (and typically more resistant) premalignant cells exposed to a cytotoxic agent. The number of premalignant-cell populations depends in turn on the background rate of critical mutations in these (and normal stem) cells that, together with the background net-proliferation rate, determine the spontaneous risk of tumor occurrence. How cytotoxicity and consequent regenerative cell renewal affect tumor risk thus depends critically on how exposure affects the balance of these contributing processes. Unless a cytotoxic exposure is very large and/or chronic. Although regenerative hyperplasia alone (a purely cytotoxic MOA) may often fail to boost these processes enough to increase tumor rates detectably in typical bioassay studies, it is well recognized to be effective in certain cases. Repeated or chronic administration of carbon tetrachloride very likely has a purely cytotoxic MOA, greatly amplified via magnifying the background mutation rate by prior administration of a single, initiating dose of a potent mutagen like diethylnitrosamine, aflatoxin or ionizing radiation (Solt et al., 1983; Brunius, 1987; Bogen, 1990; Columbano et al., 1990; Kotsanis and Metcalfe, 1991) . A similar argument be made for other carcinogens that (due to cytotoxic or other mechanisms) induce sustained cell proliferation and/or suppress apoptosis, but that have at best very weak in vivo genotoxicity, such as: catechol; chloroform; chronic infection by certain microbes such Helicobacter pylori); peroxisome proliferators such as di(2-ethylhexyl-phthalate (DEHP); agents such as d-limonene and unleaded gasoline that induce adducted-α2u-globulin-mediated hyaline-droplet-induced nephrotoxicity and cell proliferation in male rats; sesamol; sodium saccharin and other agents that can induce bladder-irritating urinary calculi; and the mitogenic promoter 12-o-tetradecanoyl phorbol-13-acetate (TPA) Ellwein, 1990,1991; Dietrich and Swenberg, 1991; USEPA, 1991 USEPA, ,2003 Rodgers and Baetcke, 1993; Larson et al., 1994; IARC, 2003; Holmes and Rainsford, 2002; Solnick and Schauer, 2001 ). Thus, in the case of BHA, an expert working group concluded that "For some carcinogens not known to be genotoxic …, irritation leading to enhanced and sustained cell proliferation may be essential for tumour development. … Non-DNA reactive agents such as butylated hydroxyanisole appear to cause forestomach tumours primarily through initial cytotoxicity and subsequent sustained cell proliferation and hyperplasia" (IARC, 2003) .
Of course, there is by definition no increased tumor risk associated with cells that are killed by a cytotoxic agent, which occurs more readily if premalignant cells have no selective
advantage (e.g., via reduced metabolic-activating capability, enhanced levels of GHS or other detoxifying activity, etc.) over their normal neighbors, as may be the case for certain directacting toxicants and for ionizing radiation. For this reason, "cell proliferation is not necessarily a tumor promoter or cocarcinogen" (Melnick et al., 1996; Ward et al., 1993 ) and regenerative hyperplasia is not always associated with increased tumor risk. Nevertheless, it has long been well recognized that sustained cell proliferation may contribute to tumor development caused by chronic chemical exposures that are both genotoxic and cytotoxic (Schulte-Hermann et al., 1983; Ward et al., 1993; IARC, 2003)-i.e. , that values of F h > 1 can and do occur-as illustrated by the effectiveness of initiation-promotion protocols, and by DMOA carcinogens, including tissuespecific or contact irritants that can also damage DNA, such as formaldehyde (Conolly et al., 2004) , ethyl acrylate (Ghanayem et al., 1986; Ciaccio et al., 1998) , vinyl acetate (Hengstler et al., 2003) , tetranitromethane (TNM) (Bucher et al., 1991; Murata et al., 1996) and, as proposed here, naphthalene.
For DMOA carcinogens, the Guidelines recommend that "An analysis of model uncertainty can be used to determine the range where extrapolation using the toxicodynamic model is supported and where further extrapolation would be based on either a linear or a nonlinear default, as appropriate" (see Appendix). This recommendation begs the question of how to avoid the "catch-22" problem described above. Specifically, the Guidelines imply that even when clear evidence that a DMOA is operative, its mechanistic basis and entire doseresponse must be understood completely-a virtually impossible task, without solving the general puzzle of cancer itself-before evidence of that DMOA will be reflected in the doseresponse model actually applied by EPA for risk assessment (although associated uncertainty may be "explored" by modeling). Consequently, risk assessments for DMOA carcinogens may lack scientific credibility.
While the Guidelines for Carcinogen Risk Assessment offer no clear solution to this dilemma, there is ample precedent to address it reasonably and explicitly-without requiring virtually insurmountable hurdles in the form of exhaustively validated toxicokinetic modelsusing standard procedures from the USEPA "reference dose" process (USEPA, 2002), when available evidence so warrants. In the hypothetical case above, for example, such an approach might be warranted in the special circumstance that all relevant background tumor rates are extremely small (e.g., <10 -3 ). In this circumstance, despite the fact that available toxicokinetic data might be insufficient to fully validate a toxicokinetic model applicable to environmental levels of risk extrapolation, those data could be sufficient to conclude with reasonable certainty that linear risk extrapolation assuming a fully genotoxic MOA from a "point of departure" derived from bioassay data will substantially overestimate (e.g., by ≥2-fold) true incremental risk at very low doses. One context in which such reasonable certainty can arise is proposed here, namely, when:
(I) histological evidence confirms that observed tumor response rates at all dose levels of each positive bioassay have almost certainly been augmented by dose-related, histologically associated (e.g., cell-killing induced regenerative) hyperplasia, and (II) supplemental toxicokinetic data establish that any dose-related genotoxicity is invariably accompanied by similar hyperplasia reasonably expected to amplify any purely genotoxic tumor risk, according to a biologically based multistage (e.g., MVK) model parameterized in a way constrained to reflect the maximum genotoxic tumor risk that is plausible conditional on all relevant data.
If conditions I and II hold in this hypothetical case, it should be possible to estimate from the constrained MVK model the minimum plausible factor, Min(F h ), by which linear genotoxic extrapolation overestimates the true low-dose cancer risk that is consistent with the available data.
Along these lines, it is proposed that low-dose risk implications of DMOA uncertainty can be addressed using mechanistic toxicokinetic models that incorporate physiologically based pharmacokinetic (PBPK) and 2-stage stochastic carcinogenesis (MVK) model components, which in turn are sufficiently general to reflect a DMOA assumption. Specifically, in the special case when all relevant target tumor types happen to be extremely rare, evidence may be sufficient to characterize and address DMOA uncertainty in particular, and its low-dose implications for risk extrapolation, with reasonable confidence based on mechanistic modeling.
Here, this idea is applied to the carcinogen naphthalene, which EPA recently proposed to reclassify based on NTP bioassay data indicating increased risk of very rare nasal tumors in rats, in addition to earlier NTP and other data indicating increased risk of lung tumors in mice (USEPA, 1998 (USEPA, , 2004 . Specifically, the proposed method to address MOA uncertainty for DMOA carcinogens is applied to risk extrapolation from bioassay data on naphthalene-induced tumors in rats. To do so, this illustrative application
(1) combines bioassay and in vitro data with PBPK modeling results to show with high confidence that naphthalene is a DMOA carcinogen (see Section 2.1);
(2) obtains plausibility bounds on rat-tumor-type specific DMOA-related uncertainty, using an MVK model parameterized to reflect in vitro data that link genotoxic and cytotoxic action of 1,2-and 1,4-naphthoquinone (the most potent identified genotoxic naphthalene metabolites); and (3) derives, from plausibility bounds obtained in step (2), corresponding "adjustment" factors <1 appropriate to apply to naphthalene risks that are estimated more conservatively by linear extrapolation under the default genotoxic MOA assumption.
To address step (1), key bioassay and toxicokineitc data were reviewed and recently developed PBPK models for naphthalene were applied to assess a mechanistic basis for site-and speciesspecific target-organ cytotoxicity. MVK modeling results are next presented that incorporate in vitro data relating naphthalene mutagenic to cytotoxic potency. The MVK modeling results were then used to obtain corresponding "adjustment" factors by which estimates of naphthalene risk based on linear extrapolation under a default genotoxic MOA assumption should be reduced in order to reflect the likely dual MOA (DMOA) for naphthalene carcinogenicity. Each of the steps above is discussed in the corresponding sections below.
All calculations reported below were performed using Mathematica 5.0 ® software (Wolfram, 1999) , using methods described below.
Mode of Carcinogenic Action for Naphthalene
Key data are reviewed here concerning the ability of naphthalene to induce cancer in rodents (Section 2.1); concerning naphthalene metabolism and related cytotoxicity (Section 2.2);
and concerning genotoxicity of naphthalene and its metabolites, and its relation to associated cytotoxicity (Section 2.3). Recently developed PBPK models for naphthalene are applied in Section 2.4 to assess a mechanistic basis for site-and species-specific target-organ cytotoxicity of this compound, in light of information reviewed in Sections 2.1 -2.3. Information from Sections 2.1-2.4 are then used to infer a MOA for naphthalene-induced rat nasal tumors in Section 2.5.
Naphthalene Carcinogenicity
Case reports of cancer in naphthalene-exposed humans involve four laryngeal cancer cases among smokers in workers at an East German naphthalene purification plant (Kup, 1978; Wolf, 1976 Wolf, , 1978 , and a series of 11 colorectal carcinoma patients 18 to 30 years old admitted to a Nigerian hospital, "half" of whom "gave a definitive history of ingesting" the "naphthalene compound" kafura used as part of "local indigenous treatment for 'piles' or any anorectal problem" (Ajao et al., 1988) . These case reports have been considered insufficient to evaluate human carcinogenicity of naphthalene (USEPA, 1998 (USEPA, , 2004 IARC, 2002) . Incidences of alveolar/bronchiolar adenomas or carcinoma were increased in female (but not male) B6C3F1 mice exposed to 30 (but not to 10) ppm naphthalene for 2 years (NTP, 1992; Abdo et al., 1992) .
A previous study found increased tumor multiplicity in tumor-bearing A/J strain mice exposed to 10 or 30 ppm for 6 months (Adkins et al., 1986) . More recently, increased incidences of rare respiratory epithelial adenomas and of rare olfactory epithelial neuroblastomas were observed in female rats, and rare respiratory epithelial adenomas were observed in male rats, exposed to naphthalene vapor concentrations of 10, 30, or 60 ppm for 2 years (NTP, 2000; Abdo et al., 2001; Long et al., 2003 (NTP, 1992 (NTP, , 2002 Abdo et al., 1992) . Histopathology findings from this study are consistent with DMOA carcinogenesis, particularly in view of related cytotoxicity information from other studies. Chronic naphthalene exposures at these levels produced dose-dependent cytotoxicity in the same (distal-bronchial/alveolar) lung region in mice, but not in rats (West et al., 2001 ). Relative to neighboring cells, non-ciliated Clara cells exhibited particularly high susceptibility to naphthalene-induced cytotoxicity. These cells also demonstrate the greatest capacity to metabolize naphthalene, as discussed below. General, granulomatous and glandular inflammation and alveolar epithelial hyperplasia were all significantly elevated among the highdose female mice. "Alveolar epithelial hyperplasia occurred primarily in or adjacent to areas of inflammation" (Abdo et al., 1992) . In earlier studies, a single 125-or 250-mg/kg ip injection of naphthalene was sufficient to cause bronchial and bronchiolar epithelial necrosis in mice (Mahvi et al., 1977 , Tong et al., 1981 . Mild to moderate nasal respiratory epithelial hyperplasia also occurred in 100% of all dosed female and in >95% of all dosed male mice, but in virtually none of the control mice.
Histopathology findings obtained from the NTP (2000) rat bioassay provide clear evidence that nasal tumor formation in rats chronically exposed to naphthalene by inhalation was at least substantially influenced, if not driven primarily, by chronic tissue damage and associated regenerative and focal hyperplasia. The extent of chronic nasal cytotoxicity and hyperplasia detected in nearly 100% of all exposed animals (regardless of dose group) was described by Long et al. (2003) as follows (bold added):
"Neuroblastomas occurred amid a complex spectrum of nonneoplastic lesions of the olfactory epithelium. The principal nonneoplastic proliferative lesion was atypical hyperplasia, which … consisted of proliferating nests of dysplastic olfactory epithelial cells … and/or multifocal nodular proliferations of basal cells extending into the submucosa …. The hyperplastic cells were deeply basophilic and, in many areas, continuous with the neoplasms. Such continuity was most clearly observed in association with small neuroblastomas. Atrophy of olfactory epithelium was characterized by … loss of epithelial cells … there was also loss of olfactory neurons. The most severe lesions had complete loss of sustentacular cells and neurons, leaving only basal epithelial cells.
Respiratory epithelial adenomas also occurred amid a spectrum of non-neoplastic lesions of the respiratory epithelium and the submucosal glandular epithelium. … In a few animals, focal proliferation of hyperplastic cuboidal respiratory epithelium resembled early adenoma formation.
… Although the incidence and severity of these non-neoplastic lesions frequently increase in an exposure-dependent manner, they commonly occur with no evidence of nasal carcinogenicity, indicating that factors other than the extent of tissue injury from chronic nasal toxicity contribute to nasal carcinogenesis … . Atypical hyperplasia of the olfactory basal cells occurred at very high frequencies in all male and female groups exposed to naphthalene. This was considered an unusual proliferative lesion, because it had not been reported in previous NTP inhalation studies. Morphologically, these cells were similar to, and frequently formed a continuum with, those of the neuroblastomas. This appearance suggests that the atypical hyperplasia may represent a precursor for nasal olfactory carcinogenesis. In addition, a few animals had localized proliferative changes of the respiratory epithelium that were morphologically similar to respiratory epithelial adenomas. "
This description of cytotoxicity and hyperplasia, in direct association with the observed nasal neuroblastomas and nasal respiratory epithelial adenomas, is similar to descriptions of multistep neoplastic transformation from focal hyperplastic tissue to nodular hyperplasia to adenomas or carcinomas observed in chemically induced or promoted carcinogenesis in the rodent liver and gastrointestinal tract (Farber, 1984; Farber and Cameron, 1984; Pitot et al., 2000) . While initiation with a genotoxic agent is typically used in these experimental rodent carcinogenesis systems in order to generate observable tumor rates, subsequent promotion involving either enhanced cell proliferation, or just oxidative stress associated with additional genotoxic or cytotoxic exposure(s) (Sanchez-Perez et al., 2005) , can be required to elevate these rates to observable levels.
Naphthalene was clearly cytotoxic to epithelial and neural cells in nasal tissue of exposed NTP (2000) bioassay rats. The observed cytotoxic damage and histologically linked regenerative hyperplasia strongly support the hypothesis that these effects likely amplified the incidence of tumor occurrence in that study, through clonal expansion of premalignant cell populations that then became available for subsequent malignant transformation (Moolgavkar, 1983; Bogen, 1989) . As further discussed below, a site-specific genotoxic MOA appears also to have been involved, as may be indicated by absence of nasal tumors in similarly exposed mice, despite evidence of (somewhat less severe) nasal epithelial hyperplasia and tissue damage (NTP, 1992; Abdo et al., 1992) . Because a cytotoxic MOA contributed to those tumors to an unknown but clearly nonzero extent, fundamental MOA uncertainty is intrinsic to any estimate of low-dose cancer risk associated potential genotoxicity that may also have contributed to rat nasal tumor formation in the NTP (2000) bioassay. However, the fact that such fundamental MOA uncertainty exists does not negate the histological evidence, referred to above, that clearly link regenerative hyperplasia to adjacent, surrounding and/or nearby neoplasia in naphthalene-exposed rats.
Naphthalene Metabolite Cytotoxicity
Naphthalene is metabolically activated by one or more forms of cytochrome P450 (CYP) to a chiral 1,2-epoxide, which can react directly to form covalent adducts with cellular nucleophiles such as DNA and protein, or undergo subsequent transformation to other reactive metabolites (including 1,2-and 1-4-naphthoquinones) or to detoxified intermediates that are excreted, primarily in urine (Buckpitt and Franklin, 1989; Buckpitt et al., 2002; Waidyanatha et al., 2002; EPA, 2004; ATSDR, 2005) . CYP-mediated metabolic bioactivation of naphthalene varies considerably among species and among different anatomical regions of the respiratory tract; it correlates with observed region-, organ-and species-specific susceptibility to naphthalene-induced cytotoxicity and carcinogenicity (O'Brien et al., 1985; Buckpitt and Bahnson, 1986; Buckpitt et al., 1992 Buckpitt et al., , 1995 Buckpitt et al., , 2002 Thornton-Manning and Dahl, 1997; Baldwin et al., 2004 Baldwin et al., , 2005 Boland et al., 2004) .
Glutathioine-S-transferase (GST) activity is a key barrier to cytotoxicity associated with reactive naphthalene metabolites, and glutathione depletion before naphthalene exposure enhances acute naphthalene-induced injury in mouse-lung Clara cells, which are observed to be early and relatively susceptible targets of cell killing that occurs at all concentrations associated with naphthalene-related lung tumorigenesis (Warren et al., 1982; West et al., 2000; Plopper et al., 2001; Phimester et al., 2004 Phimester et al., , 2005 . Greater susceptibility of cells in terminal/distal vs. upper lung regions to naphthalene-induced cytotoxicity in mice, or to ozone-induced cytotoxicity in monkeys, is not explained by regional differences in rates of glutathione resynthesis (Duan et al., 1996) . In isolated murine Clara cells, decreased cell viability was non-detectable at naphthalene is substantial (≥63%) at naphthalene concentrations ≥0.5 mM, but is blocked by preincubation with the CYP inhibitor, piperonyl butoxide (Chichester et al., 1993) . In those isolated cells, incubation with a 0.5-mM concentration of naphthalene, its dihydrodiol, 1-naphthol, or 1,2-naphthoquinone all decrease cell viability to about the same degree; however, this concentration of naphthalene oxide or 1,4-naphthoquinone causes even greater cytotoxicity, unblocked by piperonyl butoxide (Chichester et al., 1993) . In isolated mouse-lung Clara cells exposed to naphthalene, 1,2-naphthoquinone was one of two detected types of covalent, naphthalene-related protein adduct (Zheng et al., 1997) . Glutathione depletion alone appears not to explain the necrotic response of murine Clara cells to naphthalene; rather, ultrastructural studies indicate that this cytotoxic response appears to require mitochondrial damage induced by reactive naphthalene metabolites (Phimester et al., 2005) . Inhaled (but not ip-administered) naphthalene induces dosedependent Clara cell cytotoxicity in mice, whereas the same cell type does not exhibit this sensitivity in rats (West et al., 2001 ).
Necrosis of bronchial epithelial (Clara) cells in mice (Tong et al., 1981; Buckpitt and Warren, 1983; O'Brien et al., 1985 O'Brien et al., , 1989 and necrosis of olfactory epithelial cells in mice, rats and hamsters following intraperitoneal injection of naphthalene strongly indicate that metabolic activation in target tissues plays a dominant, and possibly exclusive, role in site-specific naphthalene cytotoxicity. There is no evidence that unmetabolized naphthalene is cytotoxic.
Human liver microsomes convert naphthalene to its dihydrodiol intermediate at faster
rates than mouse and rat liver microsomes (Kitteringham et al., 1996) . The human enzyme that is orthologous to the mouse CYP2F2 enzyme is CYP2F1. The CYP2F1 mRNA has been identified in human respiratory tissues by a number of different laboratories (see Raunio et al., 1999; Ding and Kaminsky, 2003) . The CYP2F1 enzyme is expressed in lymphoblastoid cells
where it metabolizes naphthalene to its epoxide, albeit at very low rates (Lanza et al., 1999) .
Immunolocalization failed to detect CYP2F in rhesus macaque tissue of any kind studied other than nasal ethmoturbinates, where levels were 10-and 20-fold lower than in corresponding rat and mouse tissue, respectively (Baldwin et al., 2004) . Pooled human liver microsomes (pHLMs)
can metabolize naphthalene to trans-1,2-dihydro-1,2-naphthalenediol (dihydrodiol), 1-naphthol and 2-naphthol; further pHLM metabolism of 2-naphthol produces 2,6-and 1,7-dihydroxynaphthalene, whereas dihydrodiol and 1-naphthol are not efficiently metabolized by pHLMs (Cho et al., 2006) .
Correlation of Genotoxicity and Cytotoxicity Induced by Naphthalene Metabolites
Prokaryotic and eukaryotic in vitro study results indicate that without metabolic activation, naphthalene itself does not damage DNA (Schreiner, 2003) . In contrast to the parent compound, naphthalene metabolites, such as 1,2-and 1,4-naphthoquinone, were found to be positive for genotoxicity in a relatively small subset of prokaryotic and eukaryotic in vitro studies involving metabolic activation (Arfsten et al., 1994; Flowers-Geary et al., 1996; NTP, 1992; Wilson et al., 1995 Wilson et al., , 1996 Sasaki et al., 1997; Yu et al. 2002; Schreiner, 2003) . The clearest evidence for this involved human lymphoid cells exposed to 1,2-and/or 1,4-naphthoquinone. After 2 hours of exposure to 0.1 µg/mL (0.63 µM) 1,4-naphthoquinone, MCL-5 human B-lymphocytes (which express several transfected CYP and epoxide hydrolase genes) exhibited a significant (~2-fold) increased frequency of micronuclei, but not of mutation frequency at the TK -or the HPRT -locus assayed (Sasaki et al., 1997) . The mutation assay performed was associated with substantially decreased (66 ± 20%) cell survival, but not the micronuclei assay. Human mononuclear lymphocytes (MNL) exposed to various concentrations of naphthalene, 1,2-epoxynaphthalene, 1-napthol, 1,2-naphthoquinone or 1,4-naphthoquinone were assayed for glutathione (GSH) depletion, for cytotoxicity and for sister chromatid exchange (SCE) frequency by Wilson et al. (1996) . Exposure for 2 hours to the 1-napthol metabolites, 1,2-naphthoquinone or 1,4-naphthoquinone, were observed to be directly toxic to MNL and to deplete GSH to up to 1% of control levels (Wilson et al., 1996) . Cytotoxicity data from this study, replotted in Figure 1 , indicate that cell killing by both of these naphthalene metabolites is modeled reasonably well as a linear function of log concentration. Note that the relationship shown in Figure 1 predicts the average amount of cell killing observed for cells exposed to 0.1 µg/mL = 0.63 µM 1,4-naphthoquinone, by Sasaki et al., 1997 . predicted to be accompanied invariably by substantially increased likelihood of cell death due to cytotoxicity. Notably, naphthalene 1,2-epoxide (2 hours at 1 to 100 µM) was found in the same study to cause neither GSH depletion, cytotoxicity, nor SCE induction (Wilson et al., 1996) .
Cytotoxicity was observed in MNL exposed for 2 hours to 10 or 100 µM concentrations of either naphthalene and 1-naphthol in the presence of rat liver microsomes, but the response to 1-naphthol (approaching that due to equal concentrations of 1,2-or 1,4-naphthoquinone) far exceeded that to naphthalene (Wilson et al., 1996) .
The pattern shown in Figure 2 exhibits a strong, positive, non-threshold association similar that observed between genotoxicity and cytotoxicity exhibited by other classes of mutagenic, carcinogenic and antineoplastic agents, such as chemical alkylating agents (Sanderson et al., 1991) and ionizing radiation (Stewart, 2001) . Data used to derive Figure 2 were selected (conservatively) to represent the combination of available data reflecting the greatest genotoxic potency with plausibly linear low-dose dose-response, combined with the least associated cytotoxicity (i.e., reflecting the smallest plausible ratio ρ = RR death /RR mut of cytotoxic to mutagenic potency), that was likely to have occurred when bioassay rats were dosed with naphthalene. The value of ρ may be concentration-dependent, as reflected in the nonlinear relation shown in Figure 2 , and perhaps also tissue-dependent. The value of ρ varies directly with the magnitude S of risk overestimation that occurs under a genotoxic MOA assumption when a DMOA is true involving cytotoxicity-driven hyperplasia, as predicted by a 2-stage MVK-type cancer-risk model of the type applied later (Section 3). For example, ρ = 0 and S = 1
(indicating no such overestimation) for any carcinogen with a purely genotoxic MOA. To conservatively estimate the value of S via the method proposed in Section 3, the smallest value of ρ should be used that is plausibly consistent with relevant available data. In the context of observed naphthalene-induced tumors in rats and mice, given available cytotoxicity and genotoxicity data discussed above, it is proposed that the function plotted in Figure 2 reflects a lower plausible bound on the value of ρ as a function of RR mut , where SCEs are used here as a surrogate measure of maximum plausible mutagenic effect.
PBPK-Based Prediction of Site-and Species-Specific Naphthalene Cytotoxicity
Physiologically based pharmacokinetic (PBPK) models developed for naphthalene (Sweeney et al., 1996) , and for naphthalene and its 1,2-epoxide metabolite and associated reaction products (Quick and Shuler, 1999; Ghanem and Shuler, 2000; Willems et al., 2001) , have been used to describe and explore plausible measures of biologically effective dose pertaining to naphthalene toxicity and carcinogenicity. PBPK model parameters governing naphthalene metabolism for the earlier models were estimated entirely from in vitro metabolic data, and then were compared and/or partially optimized to previously published data on levels of naphthalene in blood, tissue-specific GSH, and 14 C-radiolabeled adducts covalently bound to tissue-specific macromolecules in mice and rats exposed in vivo to naphthalene by intravenous (iv) injection, intraperitoneal (ip) injection, or oral dosing (Sweeney et al., 1996; Quick and Shuler, 1999; Ghanem and Shuler, 2000) . The Quick and Shuler (1999) model, summarized in Figure 3 , predicts detailed, time-dependent patterns of covalent binding and GSH depletion in lung and in liver of mice administered naphthalene by ip injection that were shown to be reasonably consistent with a range of previously published data, including detailed data reported by Warren et al. (1982) for mice ip-injected with radiolabeled naphthalene. ways. First, all naphthalene-specific model compartments were restructured to reflect a "distributed blood" assumption that intra-compartment naphthalene distribution is limited by diffusion rather than by blood flow (i.e., perfusion). The "distributed blood" framework was developed by Kohn (1997) , who showed this approach to provide a more realistic model the kinetics of respiratory 1,3-butadiene uptake by mice. Second, Willems et al. (2001) replaced the submodel for glutathione (GSH) turnover used by Quick and Shuler (1999) with the generic GSH model incorporated into the PBPK model otherwise developed specifically for 1,3-butadiene (Kohn and Melnick, 2000) . Using this modified PBPK model, Willems et al. (2001) estimated parameters governing CYP-mediated naphthalene metabolism in both liver and lung by fitting model predictions for naphthalene in chamber air in rats exposed for 6 hours (once, or daily for two weeks) to concentrations of 10, 30 or 60 ppm naphthalene, and for naphthalene in blood of mice exposed for 6 hours (once, or daily for two weeks) to concentrations of 10, 30 or 60 ppm naphthalene-i.e., using respiratory exposure protocols similar to those used in the NTP obtained in vivo data on naphthalene uptake and distribution in rats and mice. This model also predicted patterns of tissue-specific GSH depletion that appear to provide some insight into why lung might be much more susceptible to naphthalene-induced cytotoxicity than liver. Figure 4 shows tissue-specific relative GSH concentrations predicted by the Willems et al. (2001) model in 0.5-kg male rats exposed for 6 hours to 10 ppm naphthalene by inhalation. This model consists of the system of linear and nonlinear ordinary differential equations and parameter definitions defined by Willems et al. (2001) and papers cited therein, here implemented using Mathematica 5.0 ® software (Wolfram, 1999) . Willems et al. (1999) for rats exposed to naphthalene in air, relative to those in non-exposed animals, in liver (red curve) and lung (blue curve). (Left) GSH levels predicted in rats exposed to 10 ppm naphthalene as functions of time; (right) GSH levels after 6 h of respiratory exposure as a function of naphthalene air concentration.
right panels of the " Figure 5 " that appears in the study by Willems et al. (2001) . That figure from that study showed results corresponding to a 5 day/week pattern of 6-hour respiratory exposures over a 3-week period (in contrast to the 6-hour time frame shown in Figure 4 ), demonstrating that repeated previous exposures have very little effect on tissue-specific levels of GSH depletion predicted after 6 hours of respiratory exposure to naphthalene.
Species-and site-specific predictions of cytotoxicity based on PBPK modeling can provide a mechanistic, experimentally testable basis for toxicokinetic models applicable to cancer risk extrapolation. In view of data indicating the critical role of GSH depletion in cytotoxicity that can be induced by naphthalene or its metabolites discussed earlier, PBPK-model predictions of species-, sex-and site-specific differences in such GSH-depletion offer critical mechanistic insight into the potential role that cytotoxicity may have played in dose-response observed in naphthalene cancer bioassays. However, a prerequisite for such interpretation is PBPK model validation that includes reasonable agreement with a range of relevant experimental observations. In this regard, GSH predictions like those shown in Figure 4 are questionable in view of the fact that analogous predictions made by the Willems et al. (2001) model for mice exposed to 200 mg/kg naphthalene by ip injection ( Figure 5 ) deviate markedly from relative GSH measures reported by Warren et al. (1982) (reprinted in Figure 6 , below). In particular, note the substantially different appearance between predicted tissue-specific temporal patterns of GSH level shown in Figure 5 (left) vs. corresponding data shown in Figure 6 (panels a and c),
and likewise between predicted tissue-specific patterns of GSH level as functions of dose shown in Figure 5 (right) vs. corresponding data shown in Figure 6 (panels e and g).
Although, as noted above, experimental data reported by Warren et al. (1982) were modeled fairly well by the flow-limited PBPK model of Quick and Schuler (1999) , the parameters governing CYP-mediated naphthalene metabolism used in that model were estimated directly from in vitro rather than in vivo data, and it moreover relied on potentially unrealistic submodel structures for GSH-turnover and for tissue-specific naphthalene partitioning. These issues were all addressed in the model of Willems et al. (2001) , but this presumably more realistic model evidently fails to predict key empirical data that were predicted fairly well by the
Quick and Schuler (1999) model. It is not clear whether or to what extent Willems et al. (2001)
intended their PBPK model to agree with specific sets of previously published experimental data concerning naphthalene metabolites or GSH depletion, rather than to provide an initial basis for model development and exploration, since that study included only comparisons between predictions made by their model and corresponding sets of in vivo data they reported for chamber-air or blood concentrations of naphthalene in mice or rats exposed to naphthalene by inhalation or by iv injection. . Tissue-specific levels of covalent binding (left axes) and relative glutathione (GSH) depletion (right axes) reported by Warren et al. (1982;  in Figures 2 and 3 from that study) and by Buckpitt and Warren (1983) for 20-to 25-g male Swiss Webster mice ip-injected with 14 C-radiolabeled naphthalene. (Panels a-d) levels predicted in mice ip-injected with 200 mg/kg naphthalene as functions of postinjection time; (panels e-h) levels 4 h after ip injection as functions of naphthalene dose. Note the substantially nonlinear, upward bend in dose-response covalent binding, and associated GSH depletion ≥50%, observed to occur in all tissues at doses ≥ ~200 mg/kg (panels e-h). This "hockey-stick" doseresponse pattern is consistent with dose-related saturation of GSH-mediated deactivation of reactive naphthalene metabolites. The WQSM model is otherwise identical in all respects to all aspects of the Willems et al. (2001) "distributed blood" model that pertains directly to naphthalene uptake, distribution and metabolism (i.e., the part of their overall model summarized by "Naphthalene" components shown on the left side of Figure 3 above).
(1) GSH-related parameters. For the WQSM model, values of selected GSH submodel parameters were changed to correspond to those measured in 20-to 25-g male Swiss-Webster mice exposed by Warren et al. (1982) to naphthalene by ip injection. Specifically, the values 1800 and 7500 µM listed by Quick and Shuler (1999) , and used by Willems et al. (2001) , for the parameter (
!
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GSHss ) specifying steady-state GSH concentration in mouse tissue x for x = lung and liver, respectively, were replaced by 706, 2434 and 1420 µM for x = lung, liver and kidney, respectively, which are the corresponding reported mean values of measures made by Warren et al. (1982) . The values 2750 and 280 µM/min listed by Quick and Shuler (1999) , and used by Willems et al. (2001) , for the parameter ( ! V max,x GST ) specifying the maximal rate of GST-mediated GSH conjugation to naphthalene oxide in the mouse tissues x = lung and liver, respectively, were replaced by 200, 1000 and 200 µM/min for x = lung, liver and kidney, respectively, determined by qualitative optimization of WQSM model predictions to tissue-specific GSH data of Warren et al. (1982) . Likewise, the values 26.4, 102 and 75.6 nmol/mg/hr cited by Kohn and Melnick (2000) , and used by Willems et al. (2001) , for the parameter ( ! V max,x GGS ) specifying the maximal rate of GSH synthesis by γ-glutamyl synthetase (GGS) in the mouse tissues x = lung and liver, respectively, were replaced by 80, 85 and 30 nmol/mg/hr for x = lung, liver and kidney, respectively.
Parameter values used for rats were unchanged, except that the values 1800 and 7500 µM listed by Quick and Shuler (1999) , and used by Willems et al. (2001) , for the parameter (
specifying steady-state GSH concentration in rat lung and liver, respectively, were replaced by 2500, 10000 and 2000 µM for x = lung, liver and kidney, respectively, based on corresponding daytime measures in male Sprague-Dawley rats reported by Farooqui and Ahmed (1984) .
(2) Kidney metabolism. While all active mammalian cells use GSH to bind oxidative products of mitochondrial and cytosolic metabolism, key metabolizing tissues (including liver, kidney, lung and intestine) synthesize and maintain comparatively high GSH concentrations, with liver being a primary source of GSH exported in systemically circulating blood (in which 98% of the GSH is contained in red blood cells), from which GSH is transported to and extracted by other organs-principally in the kidney-as a primary source of cysteine used for (e.g., GGSmediated) intracellular GSH resynthesis (Dass et al., 1992; Lohr, 1998; Lash, 2005) . The kidney is among mammalian tissue types that express the greatest levels of GST-specific mRNA, reflecting relatively high GSH turnover in these tissues as one of the key mechanisms cells use to effectively inhibit oxidative stress that may arise from a variety of normal and pathological processes (Estonius et al., 1999; Forsberg et al., 2001 ). A PBPK model of naphthalene oxide (NO) that omits its elimination via GSH-conjugation in kidney is thus unlikely to be realistic, particularly in view of covalent binding and GSH depletion in kidney tissue of mice (but not rats) exposed to a sufficiently high dose of naphthalene (see, e.g., Warren et al., 1982; Buckpitt and Warren, 1983; O'Brien et al., 1985) .
(3) GSH-turnover submodel. For the WQSM model, NO elimination via GSHconjugation in kidney was reflected by subtracting from the expression used to model the rate dNO x (t)dt (the time derivative of NO concentration in tissue x, with x = kidney), the same form of x-specific ("ping-pong" saturation kinetics) term as those used by Quick and Shuler (1999) and Willems et al. (2001) to denote rates of GGS-mediated NO-loss in expressions representing dNO x (t)dt for liver and lung. This term also appears in tissue-specific GSH-turnover submodels used by Willems et al. (2001) , based on the generic model described by Kohn and Melnick (2000) , where this term was denoted ! v synthesis GSH, x , except that specificity to tissue x appears explicitly in the latter notation. Likewise, x-specific expressions for the rates dGSH x (t)dt and dCys x (t)dt of change in concentration of GSH and its cysteine precursor, respectively, contained in tissue x was added for x = kidney, using forms identical to those used for lung and liver tissues by Quick and Shuler (1999) and Willems et al. (2001) , except that in the WQSM model, each calculated rate constant for cysteine uptake (denoted ! v up Cys, x used in the GSH-turnover model of Kohn and Melnick, 2000) was multiplied by a corresponding term S x (t) assumed to be proportional in the following way to the ratio R x (t) = ! C x GSHss /GSH x (t) (i.e., to the magnitude of tissue-specific GSH depletion at time t):
where exponents n x were assumed to be fixed at values of 1.5, 1.5 and 8 for x = lung, liver and kidney, respectively; and W x = 1 with upper bound b = 5 were assumed for x = lung and liver.
The S x (t) term represents an assumption that active-transport-mediated uptake of extracellular cysteine actively responds to GSH depletion by increasing above its initial value term used in the GSH-metabolism model of Kohn and Melnick (2000) was replaced by the more
Using W kidney = 1, this revised GSH-turnover model was found to be unable to fit the empirical kidney GHS data obtained by Warren et al. (1982) , predicting only a gradual decline, instead of the observed sharp decline, in mouse kidney GSH at ip naphthalene doses >200 mg/kg. The observed sharp decline near that dose would, however, be explained if GSH in circulating blood-which is continuously extracted as a cysteine source by the kidney (Dass et al., 1992; Lash, 2005) -were proportional to GSH in liver, such that whenever GSH in liver (and consequently, in blood) becomes depleted below a critical threshold fraction f, cysteine extraction by the kidney becomes sharply reduced. In the WQSM model, this assumption is reflected for x = kidney by setting W x = 5[R x (t)/f] -n x for all [R x (t)] -1 < f, and W x = 1 otherwise, with f = 40%.
(4) Uptake of naphthalene administered by ip injection. Finally, Quick and Schuler (1999) assumed that ip-injected naphthalene is absorbed entirely by the liver within one minute.
The WQSM model assumes instead that only a fraction f liv of ip-injected naphthalene is absorbed directly into liver tissue with an absorption half-time of 150 min, while the remaining fraction
(1-f liv ) is absorbed entirely into the "Other" (slowly perfused) compartment (see Figure 3 ) with an absorption half-time of 30 min.
The final WQSM GSH-turnover model described predicts temporal and dose-dependent patterns of relative GSH content in liver, lung and kidney (Figure 7 ) all reasonably similar to corresponding patterns observed by Warren et al. (1982) (Figure 6 ). Figure 8 shows corresponding WQSM model predictions for mice and rats that continuously inhale naphthalene . Glutathione (GSH) concentrations predicted by the WQSM model for 22.5-g male mice and for 0.5-kg male rats exposed continuously for 6 h by inhaling the indicated air concentration of naphthalene, relative to those in vehicle-exposed animals, in liver (red), lung (blue) and kidney (green). In the plot for rats (right), in each set of red and blue curves, the lightest and uppermost curve corresponds to the base-case WQSM model, and the corresponding pair of progressively lower/darker curves reflect assumed increased maximum rates of CYP metabolism in lung by factors of 2 and 3, respectively.
at a specified air concentration for a total of 6-hour. This single-pulse respiratory exposure scenario yields results very similar to those obtained using the repeated-exposure scenario used in the mouse and rat bioassays done by NTP (1992 NTP ( , 2000 . (As noted earlier in discussing Figure 4 , although daily 6-hour exposures were used 5 days/week in those bioassays, the impact of repeated exposures on tissue-specific dynamic equilibria achieved is estimated to have been minimal.) For mice, the model predicts moderate GSH depletion in liver and kidney, and nearly complete GSH depletion in lung, at all naphthalene concentrations exceeding about 0.1 ppm (Figure 8, left) . Assuming nasal naphthalene concentrations achieved were similar to those in lung, and that nasal epithelial tissues in mice are at least as sensitive to naphthalene cytotoxicity as those in the lung, this pattern is consistent with substantial inflammation and evidence of cytotoxic/hyperplastic response observed in these tissues in some or nearly all bioassay mice at both exposure levels used, 10 and 30 ppm, with no such evidence in any other tissue at either exposure level (Abdo et al., 1992; NTP, 1992) .
For rats, the WQSM model predicts that severe GSH depletion will not occur in kidney, liver or lung at any exposure level up to 100 ppm naphthalene, which is consistent with absence of cytotoxic effects observed in any of these tissues in bioassay rats exposed daily to 6-hour levels of 10, 30 or 60 ppm naphthalene (NTP, 2000; Abdo et al., 2001; Long et al., 2003) . The pattern of GSH response to 6-hour naphthalene exposures in rat lung (Figure 8 , right) suggests that any rat tissue that might be exposed to concentrations similar to those in lung, but also produce reactive naphthalene metabolites more than about twice as rapidly as lung, would result in nearly complete GSH depletion, and thus be expected to incur cytotoxicity due to concurrent exposure to reactive naphthalene metabolites (e.g., 1,2-and/or 1,4-naphthoquinone) at naphthalene concentrations ≥ 1 ppm.
Carcinogenic MOA for Naphthalene-Induced Nasal Tumors in Rats
In the NTP rat bioassay, nearly all rats in all (10-, 30-and 60-ppm) exposure groups exhibited cytotoxic effects reflected by evident areas of cell killing, metaplasia, and mild to moderate hyperplasia in respiratory and olfactory nasal epithelia (NTP, 2000; Abdo et al., 2001; Long et al., 2003) . These bioassay results, combined with corresponding histological observations (Section 2.1) and WQSM modeling results (Section 2.4), provide arguably convincing support for the hypothesis that: (a) a substantial subset of cells contained in rat respiratory and olfactory nasal epithelia (perhaps analogous to Clara cells in mouse bronchial epithelium) have a greater capacity to metabolize naphthalene to reactive intermediates than is present in rat lung tissue, and (b) metabolism in such tissues exposed for 6 h to ≥1 ppm naphthalene will generate reactive metabolite levels that deplete GSH to levels low enough to render these metabolites cytotoxic. This hypothesis could be developed more explicitly and be tested by adapting for application to naphthalene PBPK models that incorporate nasal compartments and dynamic nasal tissue dosimetry (Anderson et al., 2000; Frederick et al., 2002; Sarangapani et al., 2002; Sweeny et al., 2004) . Such models could be parameterized using species-specific data on GSH depletion and covalent binding in nasal tissues exposed in vivo to different naphthalene concentrations in air.
A recent EPA review of naphthalene toxicity illustrates how the "catch 22" Guidelines policy regarding potential DMOA carcinogens, referred to in Section 1, has applied in the case of this chemical carcinogen. The review states (USEPA, 2004, pp. 68-69) :
"Tissue sites of nonneoplastic cellular damage (bronchoalveolar region in mice) show some correlation with tissue sites of carcinogenicity (lung tumors in mice, but not rats), suggesting that naphthalene metabolites may act by a nongenotoxic mode of action involving sustained cellular proliferation following cellular damage. However, an understanding of the mode of action is inadequate for determining why rats, but not mice, develop tumors originating in nasal epithelial tissue, even though both species show nonneoplastic lesions in nasal epithelial tissue following inhalation exposure to naphthalene. … Available evidence in support of a nongenotoxic mode of action is inadequate to preclude a mode of action involving direct covalent modification of DNA …" [emphasis added]
Thus, under the Guidelines, knowledge required to support a cytotoxic MOA must preclude the involvement of a genotoxic MOA, even if evidence supports non-negligible contribution of cytotoxicity-driven regenerative hyperplasia in amplifying whatever (if any) genotoxic component was involved in rat-nasal-tumor generation by naphthalene. The review implies that a cytotoxic MOA might be entertained if data could explain why NAP-induced cytotoxicity can cause nasal tumors in rats, but fails to do so in mice. But the species difference in this regard ignores specific histological evidence supporting the direct role of regenerative focal hyperplasia in promoting adjacent, histologically similar tumors in the nasal epithelium of NAP-exposed rats (Section 2.1). The strong likelihood of at least a DMOA (if not a purely cytotoxic MOA) was thus ignored in the risk-estimation method ultimately selected for risk extrapolation (USEPA, 2004) . The resulting approach is not scientifically credible, for naphthalene-induced rat nasal tumors, because it denies wide recognition that regenerative hyperplasia can contribute to tumor promotion (Section 1). This position is not equivalent to suggesting that regenerative hyperplasia ought always to be assumed to increase tumor likelihood whenever and wherever it occurs. However, when this (or any other) specific basis for a nongenotoxic-MOA (i.e., for a likely DMOA) contribution to elevated risk is supported by specific data in a particular case, applying an unmodified default risk-extrapolation model that presumes a purely genotoxic MOA cannot not be justified scientifically.
Biologically Based (MVK) Modeling to Bound MOA Uncertainty
Biologically based stochastic 2-stage models of carcinogenesis provide a mechanistic framework for understanding and modeling the impact on cancer risk of dynamic exposures to environmental agents that affect rates of critical stem-cell mutations, and rates of stem-cell birth and/or death (Moolgavkar and Knudsen, 1981; Moolgavkar, 1983; Bogen, 1989 ). This framework is consistent with the large body of experimental and epidemiological data supporting the view that genotoxicity as well as altered cell-growth kinetics each play critical roles that may affect environmental carcinogen dose-response Ellwein, 1990, 1991; Ames and Gold, 1990; Ames et al., 1993; Hanahan and Weinberg, 2000) The "MVK" model of carcinogenesis (Moolgavkar, 1983) NTP 2006), the background incidence rate of NREA in male rats was estimated to be 2/4000 (0.05%), while that of NRON in female (and male) rats was estimated to be less than 0/4000, which for the purpose of this analysis was approximated as 0.01%. These very low background rates of tumor incidence, combined with the lifetime (105-week) bioassay duration for rats, severely constrain biologically plausible parameterizations of any MVK model applied to explain tumor incidence rates observed in both the control and exposed animals. To illustrate this idea of bounding uncertainty in naphthalene carcinogenic MOA using the MVK framework, the following biologically realistic assumptions were used concerning model parameter values and parameter interrelationships applicable to this compound. As mentioned above, equality was assumed for stage-specific background mutation rates (m 0 ).
Values of N were presumed to be approximately 10 8 for nasal epithelial stem cells of each tumor type. Biologically plausible values for m 0 were presumed to be between 10 -8 and 10 -7 y -1 , i.e., similar to estimated values pertaining to humans (Trainor et al., 1984; King et al., 1994; Mendelsohn, 1990; Robinson et al., 1994) . The background rate b 0 of stem-cell division for nasal epithelium was assumed to be 1 y -1
, based on labeling indices <1% observed in basal lamina that serve as stem-cell reservoirs for rat nasal epithelial tissues Hotchkiss et al., 1997) . Potential linear functional dependence of m on b, implied in the formal MVK model (Moolgavkar, 1983) and also by experimental evidence (Ames et al., 1993) , was ignored here in view of the relatively minor quantitative impacts (of order [Δb] 2 ) such functional dependence can have, which in turn is due to relatively large impacts on risk that the MVK model predicts may arise from any relatively small (e.g., cytotoxicity-related) change (Δb) in value(s) of b. Equal background rates of stem-cell birth and death were assumed, reflecting the assumed, approximately constant value of stem-cell number N over the modeled post-natal rat lifespan (105 weeks). Premalignant cells generating NREA were assumed under normal conditions to proliferate at elevated rates of n b 0 assuming n = 5, consistent with n-fold (hyperplastic) elevation in turnover rates with observed values of n between 5 and 20 in putative premalignant cells that are histologically identifiable (Rotstein et al., 1986; Dragan et al., 1993; Zerban, 1994) , as well as in nasal polyps (Coste et al., 1996) . It was assumed that n = 1 for premalignant cells generating NRON, consistent with the observation that neuroendocrine cells and associated neuroepithelial bodies in mouse bronchiolar epithelium show very little if any mitotic activity and appear to be relatively resistant to chemically induced cytotoxicity (Ogawa et al., 1993) .
In all MVK models considered, premalignant cells in bioassay-exposed animals were assumed to be by some factor K less sensitive to cell killing by reactive naphthalene metabolites, in accordance with observations that repeated inhalation exposures to the naphthalene produce airway-specific Clara Cell tolerance in mouse bronchiolar epithelium (West et al., 2000a (West et al., -b, 2003 . Such induced, airway-specific Clara Cell tolerance in mouse bronchiolar epithelium was previously observed after bromobenzene exposure (Ogawa et al., 1993) , and is generally similar to exposure-induced resistance of hepatocytes to styrene toxicity observed to develop in B6C3F1 mice (Mahler et al., 1999) , resistance of murine lung tumor cells to cytotoxicity induced by xenobiotics including naphthalene (Fokert et al., 1992) , and resistance to cytotoxic drugs observed in leukemic cells (Maung et al., 1994) . Intrinsic and/or induced heterogeneity in GSH levels appears to play an important role in NAP susceptibility of Clara cells (West et al., 2000a-b) , as has also observed as a basis for cytotoxic resistance in leukemic cells (Maung et al., 1994);  however, one or more of many other known cellular strategies to reduce oxidative stress (Forsberg et al., 2001 ) may also be involved. In view of at least 4-fold variation observed in murine bronchiolar Clara-cell glutathione levels (West, 2000b) , and absent more informative data on this point, a susceptibility-reduction factor of K = 10 was assumed in this analysis. In view of the strong correlation between naphthalene-metabolite genotoxicity and cytotoxicity (Figure 2 ), the factor K was assumed also to apply to exposure-induced mutation.
In model G, the mutation rate m was assumed to increase over background rate m adjusted time-specific tumor-incidence rates were used to estimate the corresponding survival function for exposed animals with each tumor type. To fit each MOA-specific model to an adjusted, elevated tumor-incidence rate, a single corresponding MOA-specific parameter was optimized conditional on other parameter values considered biologically plausible as discussed above. Model calculations were performed using the analytic approach of Zheng (1995) , implemented using Mathematica 5.0 ® software (Wolfram, 1999) . Optimization in each case yielded a unique univariate model fit (m 0 to fit background rates, and depending on model type, either M and/or B to fit elevated rates), conditional on fixed values of the other MVK parameters described above, since the MVK-type hazard function with at most three piecewise-constant parameters is identifiable (Heidenreich et al., 1997) .
Model fits obtained for each tumor type are summarized in Table 1 and plotted in Figure 6 ) that for naphthalene this relationship is quite nonlinear, and likely is tightly related to corresponding target-cell-specific levels of glutathione depletion. Pharmacokinetic uncertainty for these tumor endpoints should be addressed separately by applying PBPK models after validation using relevant (including required new, tissue-specific) experimental data.
However, the MVK-bounding approach illustrated above supports the application of MOAspecific uncertainty factors of about 1/30 and 1/10 to linearly extrapolated risk estimates from NTP rat bioassay data on NREA and NRON tumor endpoints, respectively, if such Figure 2 . Figure 9 . MOA-specific MVK models of NREA and NRON tumor incidence in NTP bioassay rats. In each plot, the bold black (lowermost) curve shows the baseline MVK model fit to the indicated control tumor incidence rate, to which baseline all of the models considered collapse at zero dose; the bold blue (uppermost), red and green curves show models G, C and D, respectively; and the light green curve shows model D*. The jagged light black step function is the approximate survival function based on corresponding adjusted empirical bioassay survival data.
NREA NRON (1997) identifiability constraint. However, it was found that such small changes within this range affected neither fundamental MVK model behaviors nor their quantitative implications in a major way, nor corresponding conclusions reached. The models were, however, quite sensitive to values used for parameters n, K and b 0 , and conclusions reached must be interpreted with this sensitivity in mind, particularly insofar as improved estimates of these parameters could be obtained experimentally, using methods similar to those used to better understand the role of cell kinetics in formaldehyde-induced nasal tumors in rats (Monticello et al., 1996) . The proposed approach could be extended to address multiple (>2) groups of bioassay data, e.g., using formal maximum likelihood methods. … It is possible for different models to provide equivalent fits to the observed data but to diverge substantially in their projections at lower doses. When model parameters are estimated from tumor incidence data, it is often the case that different combinations of parameter estimates can yield similar results in the observed range. For this reason, critical parameters (e.g., mutation rates and cell birth and death rates) are estimated from laboratory studies and not by curve-fitting to tumor incidence data (Portier, 1987) . This approach reduces model uncertainty (see Section 3.6) and ensures that the model does not give answers that are biologically unrealistic. … Toxicodynamic modeling can provide insight into the relationship between tumors and key precursor events. For example, a model that includes cell proliferation can be used to explore the extent to which small increases in the cell proliferation rate can lead to large lifetime tumor incidences (Gaylor and Zheng, 1996) . [p. 3-14] 3.3 EXTRAPOLATION TO LOWER DOSES.
Discussion
Choosing an Extrapolation Approach
The approach for extrapolation below the observed data considers the understanding of the agent's mode of action at each tumor site (see Section 2.4). Mode of action information can suggest the likely shape of the dose-response curve at lower doses. The extent of inter-individual variation is also considered, with greater variation spreading the response over a wider range of doses.
Linear extrapolation should be used when there are MOA data to indicate that the doseresponse curve is expected to have a linear component below the POD. Agents that are generally considered to be linear in this region include:
• agents that are DNA-reactive and have direct mutagenic activity, … When the weight of evidence evaluation of all available data are insufficient to establish the mode of action for a tumor site and when scientifically plausible based on the available data, linear extrapolation is used as a default approach, because linear extrapolation generally is considered to be a health-protective approach. Nonlinear approaches generally should not be used in cases where the mode of action has not been ascertained. Where alternative approaches with significant biological support are available for the same tumor response and no scientific consensus favors a single approach, an assessment may present results based on more than one approach A nonlinear approach should be selected when there are sufficient data to ascertain the mode of action and conclude that it is not linear at low doses and the agent does not demonstrate mutagenic or other activity consistent with linearity at low doses. Special attention is important when the data support a nonlinear mode of action but there is also a suggestion of mutagenicity. Depending on the strength of the suggestion of mutagenicity, the assessment may justify a conclusion that mutagenicity is not operative at low doses and focus on a nonlinear approach, or alternatively, the assessment may use both linear and nonlinear approaches.
Both linear and nonlinear approaches may be used when there are multiple modes of action. If there are multiple tumor sites, one with a linear and another with a nonlinear mode of action, then the corresponding approach is used at each site. If there are multiple modes of action at a single tumor site, one linear and another nonlinear, then both approaches are used to decouple and consider the respective contributions of each mode of action in different dose ranges. For example, an agent can act predominantly through cytotoxicity at high doses and through mutagenicity at lower doses where cytotoxicity does not occur. Modeling to a low response level can be useful for estimating the response at doses where the high-dose mode of action would be less important. [pp, 3-21 -3-22, emphasis added] 
Extrapolation Using a Toxicodynamic Model
The preferred approach is to develop a toxicodynamic model of the agent's mode of action and use that model for extrapolation to lower doses (see Section 3.2.2). The extent of extrapolation is governed by an analysis of model uncertainty, where alternative models that fit similarly in the observed range can diverge below that range (see Section 3.6). Substantial divergence is likely when model parameters are estimated from tumor incidence data, so that different combinations of parameter estimates yield similar fits in the observed range but have different implications at lower doses. An analysis of model uncertainty can be used to determine the range where extrapolation using the toxicodynamic model is supported and where further extrapolation would be based on either a linear or a nonlinear default, as appropriate (see Sections 3.3.3, 3.3.4) . [p. 3-22] 
Extrapolation Using a Low-dose, Linear Model
Linear extrapolation should be used in two distinct circumstances: (1) when there are data to indicate that the dose-response curve has a linear component below the POD, or (2) as a default for a tumor site where the mode of action is not established (see Section 3.3.1). For linear extrapolation, a line should be drawn from the POD to the origin, corrected for background. [p. 3-23] 
Nonlinear Extrapolation to Lower Doses
A nonlinear extrapolation method can be used for cases with sufficient data to ascertain the mode of action and to conclude that it is not linear at low doses but with not enough data to support a toxicodynamic model that may be either nonlinear or linear at low doses. Nonlinear extrapolation having a significant biological support may be presented in addition to a linear approach when the available data and a weight of evidence evaluation support a nonlinear approach, but the data are not strong enough to ascertain the mode of action applying the Agency's mode of action framework. If the mode of action and other information can support chemical-specific modeling at low doses, it is preferable to default procedures.
For cases where the tumors arise through a nonlinear mode of action, an oral reference dose or an inhalation reference concentration, or both, should be developed in accordance with EPA's established practice for developing such values [involving application of "uncertainty factors" to Benchmark , no-observed-effect or lowest-observed-effect dose levels], taking into consideration the factors summarized in the characterization of the POD (see Section 3.2.5). [p. 3-23 -3-24] 
Comparing and Combining Multiple Extrapolations
When multiple estimates can be developed, all datasets should be considered and a judgment made about how best to represent the human cancer risk. [p. 3-24] 
